Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

Definium shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with major depressive disorder — with the trial meeting its primary and all key secondary efficacy endpoints.

Raccontata damorningstar.comzerohedge.comendpoints.newsbenzinga.cominvestors.com